XellSmart

About

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.

Minhang,Shanghai,China
51 - 100

Highlights

Details

Last Funding Type: Series A
Industries: Biopharma,Biotechnology,Pharmaceutical
Founded date: Jan 1, 2021
Number Of Employee: 51 - 100
Operating Status: Active
Legal Name: Shize Bio-Pharmaceutical (Shanghai) Co., Ltd.
Also Known As: 士泽生物,Shize Biologics,Shize Bio-Pharmaceutical (Shanghai) Co

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

¥77M

XellSmart has raised a total of ¥77M in funding over 2 rounds. Their latest funding was raised on Sep 7, 2022 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 7, 2022	Series A	—	10	Xiamen Jinyuan Venture Capital China Singapore Suzhou Industrial Park Ventures Eli Lilly Qiming Venture Partners	—	Detail
Sep 8, 2021	Seed	¥77M	7	Lilly Asia Ventures Qiming Venture Partners Sequoia Capital China	—	Detail

Investors

Number of Lead Investors

Number of Investors

7

14

XellSmart is funded by 14 investors. Xiamen Jinyuan Venture Capital and China Singapore Suzhou Industrial Park Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Xiamen Jinyuan Venture Capital	Yes	Series A
China Singapore Suzhou Industrial Park Ventures	Yes	Series A
Eli Lilly	Yes	Series A
Qiming Venture Partners	Yes	Series A
Lilly Asia Ventures	Yes	Seed
Trip Capital	—	Series A
Founder H Fund	—	Series A
FREES FUND	—	Series A
Junsan Capital	—	Series A
Oriza Holdings	—	Series A